New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronic acid - tablet - 70 mg - active: alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronic acid excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax is indicated: · in postmenopausal women for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures). · in postmenopausal women who are at risk of developing osteoporosis fosamax is indicated for the prevention of osteoporosis to reduce the risk of future fracture. · for the treatment of osteoporosis in men to prevent fractures. · for the treatment and prevention of glucocorticoid-induced osteoporosis in men, premenopausal women and postmenopausal women receiving oestrogen. · for treatment of paget's disease of bone in men and women.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronate anhydrous free acid; colecalciferol 140ug equivalent to 5600 iu;   - tablet - 70/140 - active: alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronate anhydrous free acid colecalciferol 140ug equivalent to 5600 iu   excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax plus is indicated for the treatment of osteoporosis in select patients where vitamin d supplementation is recommended.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - alendronate sodium trihydrate 91.37mg equivalent to to 70 mg anhydrous free acid; colecalciferol 70ug equivalent to 2800 iu;   - tablet - 70/70 - active: alendronate sodium trihydrate 91.37mg equivalent to to 70 mg anhydrous free acid colecalciferol 70ug equivalent to 2800 iu   excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax plus is indicated for the treatment of osteoporosis in select patients where vitamin d supplementation is recommended.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - tibolone 2.5mg;   - tablet - 2.5 mg - active: tibolone 2.5mg   excipient: ascorbyl palmitate lactose monohydrate magnesium stearate potato starch - · treatment of symptoms resulting from the natural or surgical menopause in post-menopausal women. women above 60 years of age should only start with livial treatment when they are intolerant of or contraindicated for other medicinal products approved for the treatment of oestrogen deficiency symptoms. · prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - desogestrel 150ug;  ; ethinylestradiol 20ug;   - tablet - active: desogestrel 150ug   ethinylestradiol 20ug   excipient: colloidal silicon dioxide dl-alpha tocopherol lactose monohydrate magnesium stearate potato starch povidone stearic acid lactose monohydrate magnesium stearate potato starch - oral contraception.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - ganirelix 0.5 mg/ml - solution for injection - 0.5 mg/ml - active: ganirelix 0.5 mg/ml excipient: acetic acid glacial acetic acid mannitol sodium hydroxide water for injection - orgalutran is indicated for the prevention of premature luteinizing hormone (lh) surges in women undergoing controlled ovarian hyperstimulation (coh) for assisted reproduction techniques (art).

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - finasteride 1mg - film coated tablet - 1 mg - active: finasteride 1mg excipient: docusate sodium hyprolose hypromellose iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose purified talc sodium starch glycolate starch titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - follitropin beta 833 iu/ml;   - solution for injection - 833 iu/ml - active: follitropin beta 833 iu/ml   excipient: benzyl alcohol hydrochloric acid as 0.1n solution to adjust to ph 7.0 methionine polysorbate 20 sodium citrate dihydrate sodium hydroxide as 0.1n solution to adjust to ph 7.0 sucrose water for injection - in the female: - anovulatory infertility - controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programmes [e.g. in vitro fertilisation and related procedures].

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - enalapril maleate 10mg - tablet - 10 mg - active: enalapril maleate 10mg excipient: iron oxide red lactose monohydrate magnesium stearate maize starch sodium bicarbonate starch - treatment of: · all grades of essential hypertension

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - enalapril maleate 2.5mg;   - tablet - 2.5 mg - active: enalapril maleate 2.5mg   excipient: lactose monohydrate magnesium stearate maize starch sodium bicarbonate